Literature DB >> 16842465

Persistence and adherence to proton pump inhibitors in daily clinical practice.

E M Van Soest1, P D Siersema, J P Dieleman, M C J M Sturkenboom, E J Kuipers.   

Abstract

BACKGROUND: Proton pump inhibitors are widely used, but little is known about the usage pattern in different indications. AIM: To analyse proton pump inhibitor usage patterns in the general population.
METHODS: A cohort of 16 311 incident proton pump inhibitor users was identified in the Integrated Primary Care Information database, a Dutch general practice research database. Persistence and adherence were calculated by indication. Risk factors were identified by logistic regression analysis.
RESULTS: One-year persistence was 31% in patients using proton pump inhibitors for gastro-oesophageal reflux. Persistence was higher in oesophagitis grade A/B (54%), grade C/D (73%) and Barrett's oesophagus (72%), compared to patients with only reflux symptoms (27%). Approximately 25% of patients with non-reflux dyspepsia or Helicobacter pylori-associated indications used proton pump inhibitors for more than 6 months. Half of all patients used proton pump inhibitors <80% of time indicating intermittent use, which was independent of indication. Exception were patients with Barrett's oesophagus, who were most adherent.
CONCLUSIONS: A substantial proportion of patients with indications not requiring long-term treatment use proton pump inhibitors for an extended period. Half of the patients used proton pump inhibitors on-demand or intermittently. Such usage pattern is probably sufficient for most patients, but may be inadequate if proton pump inhibitors are used for serious diseases, such as severe oesophagitis or Barrett's oesophagus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842465     DOI: 10.1111/j.1365-2036.2006.02982.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

2.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

3.  Proton pump inhibitors and gastric neoplasia.

Authors:  E J Kuipers
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

4.  When to stop?

Authors:  Jon Eik Zwisler; John Larsen; Lars F Gram
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

5.  Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis.

Authors:  Hsin Cheng; Yu-Ching Tsai; Wei-Ying Chen; Wei-Lun Chang; Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

6.  Population-based assessment of gastrointestinal symptoms and diseases: Cappadocia Cohort, Turkey.

Authors:  Orhan Sezgin; Hale Akpınar; Birol Özer; Murat Törüner; Kadir Bal; Serhat Bor
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

7.  An automated tool for detecting medication overuse based on the electronic health records.

Authors:  Hojjat Salmasian; Daniel E Freedberg; Julian A Abrams; Carol Friedman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-12-12       Impact factor: 2.890

Review 8.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

9.  Long-Term PPI Use: Balancing Potential Harms and Documented Benefits.

Authors:  Loren Laine; Anil Nagar
Journal:  Am J Gastroenterol       Date:  2016-04-26       Impact factor: 10.864

10.  Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Authors:  Per G Farup; Mathis Heibert; Victor Høeg
Journal:  BMC Complement Altern Med       Date:  2009-02-24       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.